指南与共识重症综合管理与镇静镇痛

免疫检查点抑制剂治疗患者免疫相关不良事件管理:ASCO指南更新

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2021-11-01
一句话结论ASCO指南更新:1级免疫相关不良事件除部分神经、血液、心脏毒性外继续ICPi并密切监测;2级可暂停ICPi并可给糖皮质激素;3级一般暂停ICPi并启动大剂量糖皮质激素;4级一般永久停用ICPi(激素替代控制的内分泌病除外)。

ASCO召集肿瘤内科、皮肤科、消化科、风湿科、呼吸科、内分泌科、神经科、血液科、急诊科、护理、试验方及患者倡导专家组成多学科小组更新指南,采用系统文献综述(聚焦2017至2021年发表的证据)与非正式共识流程,共175项研究符合系统综述纳入标准。因高质量证据缺乏,推荐基于专家共识。推荐按器官系统给出免疫相关不良事件(irAEs)的诊断与管理意见:1级毒性一般继续ICPi并密切监测(部分神经、血液、心脏毒性除外);多数2级毒性可暂停ICPi,症状恢复至≤1级时可考虑重启,可给予糖皮质激素;3级毒性一般需暂停ICPi并启动大剂量糖皮质激素,糖皮质激素应在至少4-6周内逐渐减量,部分难治病例可能需要其他免疫抑制治疗;4级毒性一般推荐永久停用ICPi,但经激素替代控制的内分泌病除外。

要点

  • 1级irAEs一般继续ICPi并密切监测,但部分神经、血液和心脏毒性例外。
  • 多数2级irAEs可暂停ICPi,症状恢复至≤1级时可考虑重启,并可给予糖皮质激素。
  • 3级irAEs一般需暂停ICPi并启动大剂量糖皮质激素,激素应在至少4-6周内逐渐减量。
  • 部分难治性irAEs可能需要其他免疫抑制治疗。
  • 4级irAEs一般推荐永久停用ICPi,但经激素替代控制的内分泌病除外。

适用人群与场景

  • 接受免疫检查点抑制剂(ICPi)治疗并发生免疫相关不良事件(irAEs)的患者。

诊断标准与关键阈值

  • 按器官系统对irAEs进行诊断与分级管理,具体分级标准见指南各器官系统章节。

处置流程与药物剂量

  • 1级毒性:一般继续ICPi并密切监测,但部分神经、血液和心脏毒性例外。
  • 2级毒性:多数可暂停ICPi,症状恢复至≤1级时可考虑重启;可给予糖皮质激素。
  • 3级毒性:一般需暂停ICPi并启动大剂量糖皮质激素;糖皮质激素应在至少4-6周内逐渐减量;部分难治病例可能需要其他免疫抑制治疗。
  • 4级毒性:一般推荐永久停用ICPi,但经激素替代控制的内分泌病除外。

红旗征与不能漏的情况

  • 部分神经、血液和心脏毒性即使为1级也不按一般1级原则继续ICPi,需按指南相应器官系统章节处理。

研究设计与关键结果

  • 系统综述共纳入175项符合纳入标准的研究,聚焦2017至2021年发表的证据,用于制定推荐。
  • 因高质量证据缺乏,推荐基于专家共识。

证据类型、等级与局限

  • 证据类型:ASCO指南更新,采用系统文献综述与非正式共识流程制定。
  • 因高质量证据缺乏,推荐基于专家共识。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 接受ICPi治疗的患者出现irAEs时,按器官系统分级决定是否继续、暂停或永久停用ICPi及是否使用糖皮质激素。
  • 1级毒性一般继续ICPi并密切监测,但部分神经、血液和心脏毒性例外。
  • 3级毒性启动大剂量糖皮质激素后应在至少4-6周内逐渐减量。
  • 4级毒性一般永久停用ICPi,但经激素替代控制的内分泌病除外。

指南或共识出处

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update(ASCO指南更新)

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.

METHODS: A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing, trialists, and advocacy experts was convened to update the guideline. Guideline development involved a systematic literature review and an informal consensus process. The systematic review focused on evidence published from 2017 through 2021.

RESULTS: A total of 175 studies met the eligibility criteria of the systematic review and were pertinent to the development of the recommendations. Because of the paucity of high-quality evidence, recommendations are based on expert consensus.

RECOMMENDATIONS: Recommendations for specific organ system-based toxicity diagnosis and management are presented. While management varies according to the organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, except for some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert ≤ grade 1. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids. Corticosteroids should be tapered over the course of at least 4-6 weeks. Some refractory cases may require other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, except for endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

参考来源

  1. Schneider, Naidoo, Santomasso, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021. PMID: 34724392. doi:10.1200/JCO.21.01440

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。